HK1253911A1 - Formulation for anti-alpha4beta7 antibody - Google Patents

Formulation for anti-alpha4beta7 antibody Download PDF

Info

Publication number
HK1253911A1
HK1253911A1 HK18113059.1A HK18113059A HK1253911A1 HK 1253911 A1 HK1253911 A1 HK 1253911A1 HK 18113059 A HK18113059 A HK 18113059A HK 1253911 A1 HK1253911 A1 HK 1253911A1
Authority
HK
Hong Kong
Prior art keywords
formulation
antibody
antigen
binding fragment
humanized immunoglobulin
Prior art date
Application number
HK18113059.1A
Other languages
English (en)
Chinese (zh)
Inventor
威洛‧迪尔卢兹奥
威洛‧迪爾盧茲奧
方．M．源
乔纳德．M．沃尔高
维斯阿纳桑．帕拉尼阿帕安
杰森．布朗
喬納德．M．沃爾高
欧文‧H‧福克斯
凯瑟琳‧肖尔茨
維斯阿納桑．帕拉尼阿帕安
艾丽卡．海伦．詹金斯
马里亚．罗萨里奥
歐文‧H‧福克斯
凱瑟琳‧肖爾茨
艾麗卡．海倫．詹金斯
馬里亞．羅薩里奧
Original Assignee
Takeda Pharmaceutical Company Limited
米倫紐姆醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1253911(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited, 米倫紐姆醫藥公司 filed Critical Takeda Pharmaceutical Company Limited
Publication of HK1253911A1 publication Critical patent/HK1253911A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
HK18113059.1A 2011-05-02 2018-10-12 Formulation for anti-alpha4beta7 antibody HK1253911A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161481522P 2011-05-02 2011-05-02
US61/481522 2011-05-02
US201161544054P 2011-10-06 2011-10-06
US61/544054 2011-10-06

Publications (1)

Publication Number Publication Date
HK1253911A1 true HK1253911A1 (en) 2019-07-05

Family

ID=46147702

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113059.1A HK1253911A1 (en) 2011-05-02 2018-10-12 Formulation for anti-alpha4beta7 antibody

Country Status (38)

Country Link
US (7) US10040855B2 (enExample)
EP (5) EP3311834A1 (enExample)
JP (6) JP6190359B2 (enExample)
KR (8) KR102136208B1 (enExample)
CN (4) CN108969761A (enExample)
AR (1) AR086238A1 (enExample)
AU (5) AU2012250872B2 (enExample)
CA (2) CA2834900C (enExample)
CL (3) CL2013003145A1 (enExample)
CO (1) CO6801648A2 (enExample)
CR (1) CR20130556A (enExample)
CY (1) CY1119436T1 (enExample)
DK (1) DK2704742T3 (enExample)
DO (1) DOP2013000252A (enExample)
EA (1) EA032625B1 (enExample)
EC (1) ECSP22046340A (enExample)
ES (1) ES2646717T3 (enExample)
GE (1) GEP20186866B (enExample)
HK (1) HK1253911A1 (enExample)
HR (1) HRP20171457T1 (enExample)
HU (1) HUE036664T2 (enExample)
IL (6) IL274846B2 (enExample)
LT (1) LT2704742T (enExample)
ME (1) ME02858B (enExample)
MX (4) MX354101B (enExample)
MY (1) MY188820A (enExample)
PE (1) PE20141672A1 (enExample)
PH (3) PH12013502237A1 (enExample)
PL (1) PL2704742T3 (enExample)
PT (1) PT2704742T (enExample)
RS (1) RS56429B1 (enExample)
SG (1) SG194730A1 (enExample)
SI (1) SI2704742T1 (enExample)
SM (1) SMT201700515T1 (enExample)
TW (5) TWI638661B (enExample)
UY (1) UY34054A (enExample)
WO (1) WO2012151247A2 (enExample)
ZA (2) ZA201308168B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP4011917A1 (en) 2010-01-06 2022-06-15 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
AU2011312191B2 (en) * 2010-10-06 2015-07-02 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
CN110711248A (zh) 2011-01-28 2020-01-21 赛诺菲生物技术公司 包含针对pcsk9的人抗体的药物组合物
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AU2012250872B2 (en) * 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
SG10201605516YA (en) 2011-07-06 2016-08-30 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9764093B2 (en) * 2012-11-30 2017-09-19 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
EP3594244A1 (en) 2013-03-15 2020-01-15 Dyax Corp. Anti-plasma kallikrein antibodies
JP6908998B2 (ja) * 2013-07-05 2021-07-28 ステラー・バイオウム・インコーポレーテッド 口腔組成物
CN106061468B (zh) * 2013-11-29 2020-10-02 阿雷斯贸易股份有限公司 包含TNFR和Fc区的融合蛋白的液体制剂
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
KR20230109785A (ko) 2014-03-27 2023-07-20 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2016057424A1 (en) 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
JP6726666B2 (ja) * 2014-12-03 2020-07-22 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリンを含む安定性が高められた医薬製品
EP3227683B1 (en) 2014-12-05 2019-04-24 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016105572A1 (en) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
BR112017020864A2 (en) * 2015-03-30 2018-07-10 Dyax Corp. plasma kallikrein inhibitors and their uses for the prevention of hereditary angioedema attack
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
IL311156A (en) 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2016380988B2 (en) * 2015-12-30 2022-07-21 Genentech, Inc. Formulations with reduced degradation of polysorbate
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
CN117298268A (zh) 2016-03-14 2023-12-29 千禧制药公司 治疗或预防移植物抗宿主疾病的方法
CA3017743A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
US11389533B2 (en) 2016-06-12 2022-07-19 Takeda Pharmaceutical Company Limited Method of treating inflammatory bowel disease
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
MX2019007564A (es) * 2016-12-23 2019-09-06 Serum Institute Of India Pvt Ltd Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion corriente abajo y formulaciones de anticuerpos estables obtenidas a partir de los mismos.
CN108686204A (zh) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 包含组氨酸缓冲体系的英夫利西单抗组合物
JP2020517671A (ja) 2017-04-28 2020-06-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小児の障害を処置する方法
EP3672994A4 (en) * 2017-08-25 2021-06-02 Omeros Corporation HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITIVE ANTIBODY FORMULATIONS, KITS, AND METHODS FOR TREATING PEOPLE WITH ATYPICAL HEMOLYTIC SYNDROME
SG11202009874QA (en) * 2018-04-10 2020-11-27 Dr Reddys Laboratories Ltd Antibody formulation
US12024561B2 (en) * 2018-04-10 2024-07-02 Dr. Reddy's Laboratories Limited Stable antibody formulation
EP3773696A4 (en) * 2018-04-10 2021-12-29 Dr. Reddy's Laboratories Ltd. Stable formulations of therapeutic antibody
US20210187107A1 (en) * 2018-08-29 2021-06-24 Glaxosmithkline Intellectual Property Development Limited Methods of preparing stable liquid therapeutic protein compositions
EP3908276B1 (en) * 2019-01-08 2025-06-11 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
EP3956358A4 (en) * 2019-04-17 2023-01-25 Millennium Pharmaceuticals, Inc. COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
MX2021015302A (es) * 2019-06-10 2022-01-18 Takeda Pharmaceuticals Co Metodos de purificacion de anticuerpos y composiciones de estos.
WO2021070203A1 (en) * 2019-10-11 2021-04-15 Dr. Reddy's Laboratories Limited Stable formulation of integrin antibody
CN115515984A (zh) * 2020-05-08 2022-12-23 亘喜生物科技（上海）有限公司 一种抗cd19抗体的抗体及其制备和应用
MX2023001157A (es) * 2020-07-31 2023-02-22 Genentech Inc Formulaciones de anticuerpo anti-integrina beta7 y dispositivos.
US20230340131A1 (en) * 2020-11-12 2023-10-26 Dr. Reddy’S Laboratories Limited Stable aqueous high concentration formulation of integrin antibody
US20240101679A1 (en) * 2020-12-09 2024-03-28 Dr. Reddy’S Laboratories Limited Stable aqueous buffer free formulation of an integrin antibody
EP4346899A1 (en) * 2021-06-04 2024-04-10 Polpharma Biologics S.A. Vedolizumab formulation
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
WO2023126411A1 (en) 2021-12-27 2023-07-06 Polpharma Biologics S.A. Vedolizumab formulation
CN119584985A (zh) * 2022-05-27 2025-03-07 索尼特生物治疗公司 Il-12-白蛋白结合结构域融合蛋白制剂及其使用方法
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
WO2025041000A1 (en) * 2023-08-21 2025-02-27 Intas Pharmaceuticals Ltd. STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-α4β7 ANTIBODY
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0303463B1 (en) 1987-08-11 1994-11-30 The Board Of Trustees Of The Leland Stanford Junior University Method to control leukocyte extravasation
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP0462111A4 (en) 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CZ282603B6 (cs) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
EP0625912B1 (en) 1992-02-12 1997-04-16 Biogen, Inc. Treatment for inflammatory bowel disease
WO1993023526A1 (en) 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
WO1994013312A1 (en) 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
JP3593343B2 (ja) 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
WO1995019790A1 (en) 1994-01-25 1995-07-27 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
MX9706049A (es) 1995-02-10 1998-02-28 Leukosite Inc Adresinas vasculares mucosas y sus usos.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6189195B1 (en) 1995-08-22 2001-02-20 Medrad, Inc. Manufacture of prefilled syringes
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
SI1485127T1 (sl) 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
PT1562940E (pt) 2002-11-18 2007-07-23 Chemocentryx Inc Sulfonamidas de arilo.
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US6886838B1 (en) 2003-01-22 2005-05-03 Zimmco Easy dumping cart
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
HRP20120171T1 (hr) 2004-09-03 2012-03-31 Genentech Humanizirani anti-beta 7 antagonisti i njihove uporabe
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1850892B2 (en) 2005-01-24 2023-04-19 Antares Pharma, Inc. Prefilled needle assisted syringe jet injector
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2006096490A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders
CA2629147A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
BRPI0710826A2 (pt) 2006-04-21 2011-08-23 Novartis Ag composições farmacêuticas de anticorpo anti-cd40 antagonista
EP2109480B1 (en) 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
AU2007331712A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2205145A4 (en) 2007-07-06 2013-06-19 Stereotaxis Inc MANAGEMENT OF A MEDICAL LIVE REMOTE DISPLAY
US20100260853A1 (en) * 2007-12-13 2010-10-14 Amrik Basran Compositions for pulmonary delivery
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
SG10201402265YA (en) * 2008-02-07 2014-08-28 Amgen Inc Stabilized protein compositions
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
CN102388068B (zh) 2009-03-20 2015-05-20 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
WO2010121141A1 (en) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
CN101533504A (zh) * 2009-04-27 2009-09-16 刘文祥 电子医务系统及其装置
EP2538973A2 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Stable antibody containing compositions
AU2012250872B2 (en) 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease

Also Published As

Publication number Publication date
JP2020180163A (ja) 2020-11-05
IL272237B (en) 2022-05-01
US20180346578A1 (en) 2018-12-06
CR20130556A (es) 2014-03-05
TWI799757B (zh) 2023-04-21
KR20190100451A (ko) 2019-08-28
AU2017204192A1 (en) 2017-07-13
JP7107997B2 (ja) 2022-07-27
KR102136208B1 (ko) 2020-07-21
MY188820A (en) 2022-01-05
SI2704742T1 (sl) 2017-12-29
UY34054A (es) 2012-11-30
MX367097B (es) 2019-08-05
US11560434B2 (en) 2023-01-24
ZA201707310B (en) 2022-04-28
KR20230021758A (ko) 2023-02-14
KR102308938B1 (ko) 2021-10-01
JP6467457B2 (ja) 2019-02-13
EP4438625A3 (en) 2024-12-11
RS56429B1 (sr) 2018-01-31
US20210340261A1 (en) 2021-11-04
IL305583B1 (en) 2025-12-01
WO2012151247A3 (en) 2013-02-28
MX384203B (es) 2025-03-14
KR102493433B1 (ko) 2023-01-27
IL274846A (en) 2020-07-30
CA2834900C (en) 2021-03-02
EA201391613A8 (ru) 2016-05-31
IL290848A (en) 2022-04-01
GEP20186866B (en) 2018-06-25
IL305583A (en) 2023-10-01
US20180327497A1 (en) 2018-11-15
CN108969469A (zh) 2018-12-11
EP2704742A2 (en) 2014-03-12
US20250034263A1 (en) 2025-01-30
US20230312727A1 (en) 2023-10-05
KR101884406B1 (ko) 2018-08-02
KR20210120144A (ko) 2021-10-06
NZ617340A (en) 2015-12-24
JP7636651B2 (ja) 2025-02-27
AU2021225160B2 (en) 2023-12-21
TW202133878A (zh) 2021-09-16
PH12013502237A1 (en) 2014-01-06
PH12018502221B1 (en) 2023-05-10
JP2017137353A (ja) 2017-08-10
KR20250093426A (ko) 2025-06-24
EP4403579A3 (en) 2024-10-16
TW201940195A (zh) 2019-10-16
EP4378959A2 (en) 2024-06-05
EP4403579B1 (en) 2025-12-10
ES2646717T3 (es) 2017-12-15
CN103533959B (zh) 2018-06-05
EA032625B1 (ru) 2019-06-28
KR20180080354A (ko) 2018-07-11
EP4438625A2 (en) 2024-10-02
TW202434293A (zh) 2024-09-01
TWI832619B (zh) 2024-02-11
HRP20171457T1 (hr) 2017-11-03
EP3311834A1 (en) 2018-04-25
JP6190359B2 (ja) 2017-08-30
TWI638661B (zh) 2018-10-21
JP2022132430A (ja) 2022-09-08
CA3051418C (en) 2021-05-18
CN107998388B (zh) 2023-07-14
IL272237A (en) 2020-02-27
PL2704742T3 (pl) 2018-01-31
IL290849A (en) 2022-04-01
CY1119436T1 (el) 2018-03-07
CO6801648A2 (es) 2013-11-29
EP2704742B1 (en) 2017-07-12
AR086238A1 (es) 2013-11-27
PH12018502221A1 (en) 2019-10-28
JP6751450B2 (ja) 2020-09-02
DOP2013000252A (es) 2013-12-31
MX2021008112A (es) 2022-06-02
TWI698254B (zh) 2020-07-11
ZA201308168B (en) 2018-11-28
TW201300128A (zh) 2013-01-01
MX2019009244A (es) 2019-09-13
AU2019216679A1 (en) 2019-09-05
AU2021225160A1 (en) 2021-09-30
US10040855B2 (en) 2018-08-07
AU2019216679B2 (en) 2021-09-23
ECSP22046340A (es) 2022-07-29
KR20170056713A (ko) 2017-05-23
US20200377601A1 (en) 2020-12-03
EP4403579A2 (en) 2024-07-24
ME02858B (me) 2018-04-20
PE20141672A1 (es) 2014-11-26
TWI723339B (zh) 2021-04-01
US20140341885A1 (en) 2014-11-20
IL229169A0 (en) 2013-12-31
CA3051418A1 (en) 2012-11-08
HUE036664T2 (hu) 2018-07-30
AU2017204192B2 (en) 2019-09-12
PT2704742T (pt) 2017-11-15
AU2012250872A1 (en) 2013-11-21
WO2012151247A2 (en) 2012-11-08
TW201813665A (zh) 2018-04-16
CN107998388A (zh) 2018-05-08
BR112013028169A2 (pt) 2017-06-27
SG194730A1 (en) 2013-12-30
AU2023274233A1 (en) 2023-12-21
AU2012250872B2 (en) 2017-07-13
DK2704742T3 (en) 2017-10-23
EP4378959A3 (en) 2024-09-04
US12286479B2 (en) 2025-04-29
LT2704742T (lt) 2017-10-25
EA201391613A1 (ru) 2014-07-30
KR102493433B9 (ko) 2023-09-01
MX354101B (es) 2018-02-13
CA2834900A1 (en) 2012-11-08
CL2017000829A1 (es) 2017-12-29
KR20140145952A (ko) 2014-12-24
CN108969761A (zh) 2018-12-11
KR101875155B1 (ko) 2018-07-09
KR20200088517A (ko) 2020-07-22
SMT201700515T1 (it) 2018-01-11
CN103533959A (zh) 2014-01-22
CL2013003145A1 (es) 2014-07-25
IL274846B1 (en) 2024-12-01
IL274846B2 (en) 2025-04-01
CL2020001579A1 (es) 2020-11-06
MX2013012725A (es) 2013-12-06
IL229169B (en) 2020-06-30
PH12019501662A1 (en) 2021-03-15
KR102014512B1 (ko) 2019-08-26
JP2014515763A (ja) 2014-07-03
TW202317193A (zh) 2023-05-01
JP2025061332A (ja) 2025-04-10
JP2019052191A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
US20250034263A1 (en) Formulation for anti-alpha4beta7 antibody
EP3263178A1 (en) Formulation for anti-alpha4beta7 antibody
HK40118152A (en) Formulation for anti-alpha4beta7 antibody
HK40112201A (en) Formulation for anti-alpha4beta7 antibody
HK40114266A (en) Formulation for anti-alpha4beta7 antibody
HK40111834A (en) Formulation for anti-alpha4beta7 antibody
HK1195485B (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
HK1195485A (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
NZ617340B2 (en) Formulation for anti-?4?7 antibody